acute myeloid leukemia

News

Integrated Palliative and Oncology Care for AML Recommended as New Standard of Care

01/05/2021

Integrated palliative and oncology care for patients with AML improves QoL, psychological stress, and end-of-life care, and researchers recommend it as a new standard of care.

Integrated palliative and...

01/05/2021

Journal of Clinical Pathways

Conference Coverage

Enasidenib Effective for Relapsed/Refractory IDH2-Mutated AML in Real-World Setting

12/06/2020

Results from a real-world study confirm the effectiveness of first-line enasidenib therapy for patients with relapsed/refractory IDH2-mutated AML outside of the trial setting.

Results from a real-world study...

12/06/2020

Journal of Clinical Pathways

News

Economic, Clinical Burden of AML Treatment Episodes in Commercially Insured Patients

07/02/2020

A new retrospective analysis highlights a “substantial economic burden” associated with key acute myeloid leukemia (AML) treatment episodes in commercially insured patients. Results of the analysis were published in...

A new...

07/02/2020

Journal of Clinical Pathways

News

Impact of NGS on Treatment Selection in AML

06/08/2020

Next-generation sequencing (NGS) has the potential to directly impact treatment decisions and outcomes in patients with acute myeloid leukemia (AML), according to a study presented at the American Society of Clinical...

...

06/08/2020

Journal of Clinical Pathways

News

Long-Term Follow-Up Data Supports Frontline Treatment Option for Older AML Patients

05/21/2020

Venetoclax plus low-dose cytarabine offers a clinically meaningful improvement in survival compared with placebo plus low-dose cytarabine in previously untreated older patients with acute myeloid leukemia (AML),...

...

05/21/2020

Journal of Clinical Pathways

News

Integrated Palliative, Oncology Care for AML Improves PROs

05/15/2020

A study to be presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program (May 29-31, 2020) highlights the results of an integrated palliative and oncology care model for patients...

A...

05/15/2020

Journal of Clinical Pathways

Research in Review

End-of-Life Care Underutilized Among Older Patients With AML

08/10/2017

JCP Editors

Use of end-of-life care and hospice services is suboptimal among older patients with acute myeloid leukemia (AML), according to a recent study published in the Journal of Clinical Oncology (online August 7, 2017;...

Use of...

08/10/2017

Journal of Clinical Pathways

Research in Review

Combination Therapy Improves Survival in a Subtype of AML

08/04/2017

JCP Editors

Addition of a multi-targeted kinase inhibitor to standard chemotherapy improves outcomes in patients with acute myeloid leukemia (AML) and a specific mutation, according to research published in The New England...

...

08/04/2017

Journal of Clinical Pathways

Research in Review

Combination Therapy Works Better in AML Patients With Activated NK Cells

08/03/2017

JCP Editors

The presence of natural killer cells can help keep acute myeloid leukemia (AML) in remission in patients treated with a combination therapy, according to a recent study. ----- Related Content Better AML Outcomes...

The...

08/03/2017

Journal of Clinical Pathways

Research in Review

Prognostic Implications of ETS2 Expression in AML

07/25/2017

JCP Editors

Elevated expression levels of ETS2 were a strong predictor of prognosis in acute myeloid leukemia (AML) and should be used to guide treatment decisions, according to recent research published in Journal of...

...

07/25/2017

Journal of Clinical Pathways